Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VBI Vaccines Inc VBIVQ

Healthcare Biotechnology
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The... see more

Recent & Breaking News (GREY:VBIVQ)

VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902

Business Wire March 9, 2021

VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2020, Provides Corporate Update and Outlook for 2021

Business Wire March 2, 2021

VBI Vaccines to Present at the Raymond James 42nd Annual Institutional Investors Conference

Business Wire March 1, 2021

VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI's 3-Antigen Prophylactic Hepatitis B Vaccine

Business Wire February 2, 2021

VBI Vaccines Announces Progress of Coronavirus Vaccine Program

Business Wire January 21, 2021

VBI Vaccines Announces Publication of Results from a Phase 4 Study of VBI's Prophylactic 3-Antigen Hepatitis B Vaccine in Vaccine

Business Wire January 15, 2021

VBI Vaccines Announces European Medicines Agency Acceptance of Marketing Authorization Application (MAA) for 3-Antigen Prophylactic Hepatitis B Vaccine

Business Wire December 23, 2020

 VBI Vaccines Selects Syneos Health as Commercialization Partner for Prophylactic 3-Antigen Hepatitis B Vaccine

Business Wire December 7, 2020

VBI Vaccines to Discuss Hepatitis B Portfolio in Virtual Fireside Chat Hosted by Raymond James

Business Wire December 2, 2020

VBI Vaccines Announces Submission of Biologics License Application to FDA for 3-Antigen Prophylactic Hepatitis B Vaccine

Business Wire December 1, 2020

VBI Vaccines Announces Submission of Marketing Authorization Application for 3-Antigen Prophylactic Hepatitis B Vaccine to the European Medicines Agency

Business Wire November 23, 2020

VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM

Business Wire November 19, 2020

VBI Vaccines Announces Positive Interim Phase 1b/2a Data for Hepatitis B Immunotherapeutic in Patients with Chronic Infection

Business Wire November 18, 2020

VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020

Business Wire November 13, 2020

VBI Vaccines Announces e-Poster Presentation at the Society for Neuro-Oncology (SNO) 2020 Virtual Meeting

Business Wire November 9, 2020

VBI Vaccines Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Business Wire November 2, 2020

VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at ID Week 2020(TM)

Business Wire October 26, 2020

VBI Vaccines to Present at the H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference

Business Wire October 15, 2020

VBI Vaccines Announces e-Poster Presentation at The Liver Meeting® 2020

Business Wire October 8, 2020

VBI Vaccines to Present at Upcoming Scientific Conferences

Business Wire September 24, 2020